search
Back to results

Cabergoline Effect on Blood Sugar in Type 2 Diabetics

Primary Purpose

Diabetes Type 2

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cabergoline
Sponsored by
Mashhad University of Medical Sciences
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Type 2 focused on measuring diabetes mellitus, FBS, HbA1C, Cabergoline

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 diabetes
  • HbA1C>7

Exclusion Criteria:

  • HbA1C>10
  • Psychiatric disorders

Sites / Locations

    Outcomes

    Primary Outcome Measures

    FBS (fasting blood sugar)

    Secondary Outcome Measures

    HbA1C

    Full Information

    First Posted
    October 24, 2011
    Last Updated
    October 24, 2011
    Sponsor
    Mashhad University of Medical Sciences
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01459601
    Brief Title
    Cabergoline Effect on Blood Sugar in Type 2 Diabetics
    Official Title
    Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2011
    Overall Recruitment Status
    Unknown status
    Study Start Date
    January 2012 (undefined)
    Primary Completion Date
    February 2012 (Anticipated)
    Study Completion Date
    February 2012 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Mashhad University of Medical Sciences

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Type 2
    Keywords
    diabetes mellitus, FBS, HbA1C, Cabergoline

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    10 (Anticipated)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Cabergoline
    Other Intervention Name(s)
    Dastinex
    Intervention Description
    0,5mg per week
    Primary Outcome Measure Information:
    Title
    FBS (fasting blood sugar)
    Time Frame
    30days
    Secondary Outcome Measure Information:
    Title
    HbA1C
    Time Frame
    30days

    10. Eligibility

    Sex
    All
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Type 2 diabetes HbA1C>7 Exclusion Criteria: HbA1C>10 Psychiatric disorders

    12. IPD Sharing Statement

    Learn more about this trial

    Cabergoline Effect on Blood Sugar in Type 2 Diabetics

    We'll reach out to this number within 24 hrs